

ROLE OF GLYPICAN-3 IN DIAGNOSIS OF HEPATOCELLULAR CARCINOMA

Thesis

*Submitted for Fulfillment of the Master's Degree in
Tropical Medicine*

By

Ismail Mohamed Abdulsamea
M.B.,B.Ch.

Supervised by

Professor Doctor/ Zakaria Yehia Mahran

*Professor of Tropical Medicine Department
Faculty of Medicine - Ain Shams University*

Doctor/ Amal Tohamy Abdel-Moez

*Assistant Professor of Tropical Medicine
Faculty of Medicine - Ain Shams University*

Doctor/ Mona Ahmed Ismail

*Assistant Professor of Clinical Pathology
Faculty of medicine - Ain Shams University*

**Faculty of Medicine
Ain Shams University
2012**

دور الجليبيكان ٣- فى تشخيص سرطان الكبد الأولى

رسالة

توطئة للحصول على درجة الماجستير فى طب المناطق الحارة

مقدمة من (الطبيب

اسماعيل محمد عبد السميع
بكالوريوس الطب والجراحة

تحت إشراف

أستاذ دكتور/ زكريا يحيى مهران

أستاذ طب المناطق الحارة

كلية الطب - جامعة عين شمس

دكتورة / أمال تهامي عبد المعز

أستاذ مساعد طب المناطق الحارة

كلية الطب - جامعة عين شمس

دكتورة / منى أحمد اسماعيل

أستاذ مساعد الباثولوجيا الإكلينيكية

كلية الطب - جامعة عين شمس

كلية الطب

جامعة عين شمس

٢٠١٢

SUMMARY

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third leading cause of cancer-related mortality after lung and stomach cancers (*Al Knawy et al., 2009*). In Egypt, the annual proportion of HCC showed a significant rising trend from 4.0% in 1993 to 7.2% in 2002 (*El-Zayadi et al., 2005*).

The aim of this study was to evaluate the diagnostic value of Glypican 3 as a tumor marker of HCC.

This study was conducted on 90 persons who were divided into three groups:

Group I (HCC group); included 30 patients with HCC on the background of liver cirrhosis. Their ages ranged between 47-65year (median=54.00).

Group II (chronic liver disease group); included 30 patients with chronic liver disease without any evidence of hepatic focal lesions as excluded by ultrasonography and AFP estimation. Diagnosis of chronic liver disease was based on standard clinical, biochemical, ultrasonographic criteria and pathological data whenever feasible. Their ages ranged between 45-61 years (median=51.50).

Group III included 30 normal subjects who served as the control group.



*First and foremost, thanks for **ALLAH** for guiding and helping me to finish this work*

*I would like to express my deepest thanks and sincere gratitude to **Prof. Zakaria Yehia Mahran**, Professor of Tropical Medicine, Faculty of Medicine, Ain Shams University, for his close supervision valuable instructions, continuous help and sincere advice.*

*Words stand short to express my deep appreciation and sincere gratitude to **Dr. Amal Tohamy Abdel-Moez**, Assistant Professor of Tropical Medicine, Faculty of Medicine, Ain Shams University, for her continuous guidance, kind encouragement and pioneer advices that put me on the right way. It was a great honor to me to work under her supervision.*

*I wish to introduce my deep respect and thanks to **Dr. Mona Ahmed Ismail**, Assistant Professor of Clinical Pathology Faculty of Medicine, Ain Shams University, for her valuable supervision, sincere advice and her immense effort in the practical part of this study.*

I am much grateful to all my colleagues in Tropical Department and HCC clinic for their co-operation and support and also to all patients included in this study.

✍ Ismail Mohamed Abdulsamea

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

﴿وَأَنْزَلَ اللَّهُ عَلَيْكَ الْكِتَابَ وَالْحِكْمَةَ وَعَلَّمَكَ مَا لَمْ
تَكُن تَعْلَمُ وَكَانَ فَضْلُ اللَّهِ عَلَيْكَ عَظِيمًا﴾

سورة النساء آية

صدق الله العظيم

(١١٣)

List of Contents

<i>Title</i>	<i>Page No.</i>
List of Tables	i
List of Figures.....	ii
List of Abbreviations.....	iii
Protocol	vi
Introduction and Aim of the Work	1
<u>Review of literature (Hepatocellular Carcinoma)</u>	
• Chapter I: Hepatocellular Carcinoma	6
• Chapter II: Management of Hepatocellular Carcinoma	31
• Chapter III: Treatment of HCC	57
• Chapter VI: Glypican 3	76
Subjects and Methods.....	89
Results	99
Discussion	122
Summary	132
Conclusion and Recommendations	134
References	136
Arabic Summary	---

List of Tables

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Tables of Review		
Table I:	Epidemiology of HCC	7
Table II:	Groups for whom HCC surveillance in recommended or in whom the risk of HCC is increased.....	32
Table III:	TNM stage grouping.....	35
Table IV:	New UICC/ AJCC staging system for hepatocellular carcinoma.....	36
Table V:	Okuda Staging Variables	37
Table VI:	Child Pugh Score	38
Table VII:	CLIP Score.....	39
Table VIII:	Japan Integrated Staging Score.....	40
Table IX:	Liver damage grade	41
Table X:	Modified Japan Integrated Staging.....	41
Table XI:	BCLC Staging System.....	42
Table XII:	Currently used Serum Tumor Markers	49
Table XIII:	Causes and Risk factors for HCC and General Approaches to prevention	74
Table XIV:	Levels of prevention against development of HCC.....	75
Tables of Results		
Table 1:	Comparison between studied groups.....	99
Table 2:	Comparison between CLD group versus HCC group as regard ultrasonographic data and child classification.....	102
Table 3:	Comparison between CLD group versus HCC group as regards laboratory data	105
Table 4:	Number and size of hepatic focal lesion in HCC group ...	107
Table 5:	Comparison between Control group versus CLD, HCC groups as regards glypican-3	108
Table 6:	Comparison between Child A, Child B and Child C in CLD patients as regards glypican-3.....	109
Table 7:	Comparison between Child A, Child B and Child C in HCC patients as regards glypican-3	110
Table 8:	Study of Glypican-3 in respect to Okuda classification in HCC Group.....	111
Table 9:	Correlations between glypican-3 and clinical parameters in CLD and HCC groups.....	112
Table 10:	Correlations between glypican-3 and laboratory parameters in CLD and HCC groups.....	113
Table 11:	Correlations between glypican-3 and US/CT parameters in CLD and HCC groups	114
Table 12:	Performance of Glypican-3 as a HCC diagnostic marker in CLD patients.....	115

List of Figures

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
-------------------	--------------	-----------------

List of Figures in Review

Figure (I)	Molecular pathogenesis of human HCC.....	23
Figure(II)	Barcelona Clinic Liver Cancer (BCLC) staging and treatment algorithm.....	58
Figure(III)	Algorithm for management of HCC	59
Figure(IV)	A suggested Egyptian algorithm for treatment of HCC according to BCLC staging	60

List of Figures (Results)

Figure (1)	ROC curve: the relation between sensitivity and 1-specificity for Glypican-3 as a marker to discriminate between control subjects and patients with LC (best cut-off point = 0.96).....	116
Figure (2)	ROC curve: the relation between sensitivity and 1-specificity for Glypican-3 as a marker to discriminate between control subjects and patients with HCC (best cut-off point = 0.96).....	117
Figure (3)	ROC curve: the relation between sensitivity and 1-specificity for Glypican-3 as a marker to discriminate between patients with LC and patients with HCC (best cut-off point = 2.55).....	118
Figure (4)	Flowcytometric analysis of HCC patient.....	120
Figure (5)	Flowcytometric analysis of HCV patient	120
Figure (6)	Flowcytometric analysis of Control	121

List of Abbreviations

AASLD	American Association for the study of the liver disease
AFB1	Aflatoxin B1
AFP	Alpha-fetoprotein
AFP L3	Lens culinaris agglutinin reactive alpha fetoprotein
AFU	Alpha-L-fucosidase
ANGs	Anghoproteins
ALP	Alkaline phosphatase
ALT	Alanine transaminase
Bax	Bcl-2 associated
BCLC	System The Barcelona-Clinic- Liver-Cancer system
BCS	Budd-Chiari syndrome
CECT	Contrast enhanced helical computed tomography
CEUS	Contrast enhanced ultrasound
CLD	Chronic liver disease
CLIP	The Cancer of the Liver Italian Program
CT	Computed tomography
CTAP	CT arterial portography
CTHA	CT during hepatic arteriography
CUPI	Chinese University Prognostic Index
DCP	Des-gamma carboxyprothrombin
DGCP	Des- γ -carboxyprothrombin
DNA	Dinucleic acid
EASL	European association for the study of the liver
EDTA	Ethylenediaminetetraacetic acid
ELISA	Enzyme-linked immunosorbent assay
FDA	Food and Drug Administration
FNAB	Fine needle aspiration biopsy
5-FU	5-fluorouracil
GCV	Ganciclovir
GGT	Gamma-glutamyltranspeptidase
GP73	Golgi protein 73
GPC3	Glypican-3
G6P	Glucose-6-phosphatase

List of Abbreviations (Cont...)

H-ALP	HCC Specific Alkaline Phosphatase
HBV	Hepatitis B virus
HCC.....	Hepatocellular carcinoma
HCV	Hepatitis C virus
HFL	Hepatic focal lesion
HGF.....	Hepatocyte growth factor
HS-GGT.....	Hepatoma-specific GGT
HSP.....	Heat shock protein
HSV	Herpes Simplex virus
HSV-tk	Herpes simplex virus thymidine kinase
hTERT.....	Human telomerase reverse transcriptase
HTN.....	Hypertension
ICGR	Indocyanine Green retention rate
ICG R15(%)..	Indocyanine Green retention rate at 15 minutes
IGF.....	Insulin like growth factor
ILP	Interstitial laser photocoagulation
IL-8	Interleukin-8
INR	International normalized ratio
IVC	Inferior vena cava
JISScore.....	The Japan Integrated Staging score
LCA.....	Lens culinaris agglutinin
LCSGJ.....	The Liver Cancer Study Group of Japan
LDH.....	Lactate dehydrogenase
LITT	Laser induced thermotherapy
LT	Liver Transplantation
MCT	Microwave Coagulation Therapy
MDCT	Multidetector helical CT
MELD	The Model for End Stage Liver Disease
MOVC.....	Membranous obstruction of the inferior vena cava
MPCT.....	Multiphasic helical CT
MRI	Magnetic resonance imaging
NASH.....	Nonalcoholic steatohepatitis
PAT	Parenteral anti-schistosomal treatment
PBMCs.....	Peripheral blood mononuclear cells

List of Abbreviations (Cont...)

PCT.....	Porphyria cutaneatarda
PDGFR.....	Platelet derived growth factor receptor
PEI	Percutaneous ethanol injection
PEIT.....	Percutaneous ethanol injection treatment
PIVKA-II	Protein induced by vitamin K absence or antagonist II
PMCT.....	Percutaneous Microwave Coagulation
PS.....	The performance status score
PSC.....	Primary sclerosing Cholangitis
PSI	Percutaneous hot saline injection
PUO	Pyrexia of unknown origin
PVE	Portal vein embolism
PVT	Portal vein thrombosis
RCT	Randomized Controlled Trial
RFA	Radiofrequency ablation
RILD.....	Radiation induced liver disease
ROC.....	The receiver operating characteristic curve
RT-PCR.....	Reverse transcription polymerase chain reaction
SCCA	Serum squamous cell carcinoma antigen
SCCAIC.....	Serum squamous cell carcinoma antigen immunocomplexes
SD.....	Standard Deviation
SELDI-TOF ..	Surface-enhanced laser desorption/ionization-time of flight mass spectrometry
sGPC3	soluble Glypican-3
SIRT	Selective internal radiation therapy
TACE	Transarterial chemoembolization
TGF- α	Transforming growth factor- α
TGF- β 1	Transforming Growth Factor-beta 1
TNM Staging System....	Tumor, Node and Metastases Staging System
UNOS.....	United Network of Organ Sharing
US	Ultrasonography
VEGF	Vascular endothelial growth factor
WHO	World Health Organization

ROLE OF GLYPICAN-3 IN DIAGNOSIS OF HEPATOCELLULAR CARCINOMA

Protocol

*Submitted for Fulfillment of the Master's Degree in
Tropical Medicine*

By

Ismail Mohamed Abdulsamea
M.B.,B.Ch.

Supervised by

Professor Doctor/ Zakaria Yehia Mahran

*Professor of Tropical Medicine Department
Faculty of Medicine - Ain Shams University*

Doctor/ Amal Tohamy Abdel-Moez

*Lecturer of Tropical Medicine
Faculty of Medicine - Ain Shams University*

Doctor/ Mona Ahmed Ismail

*Assistant Professor of Clinical Pathology
Faculty of medicine - Ain Shams University*

**Faculty of Medicine
Ain Shams University
2010**

Introduction

Hepatocellular carcinoma is a major health problem worldwide, with more than 500000 cases diagnosed annually (*Parkin et al., 2001*). HCC is the fifth most frequent tumor in the world (*Anthony, 2001*), and the most common cause of cancer related death (*Parkin et al., 2001*). While the incidence of Hepatocellular carcinoma has reportedly risen over the last 5 to 8 years, the survival of those affected has not changed significantly in the last two decades (*Bosch et al., 2004*). This is related to both its late detection and the lack of effective therapies for advanced stage disease (*Bruix & Llovet, 2002*).

Rising Prevalence in Egypt within the last two decades, this is related to both, it is late detection and lack of effective therapies for advanced stage disease. Several factors attribute the high prevalence of Hepatocellular carcinoma including cirrhosis, hepatitis C virus and hepatitis B virus. Up to 80% of Hepatocellular carcinoma develop against a background of cirrhosis of the liver and while it is believed that surveillance of the at risk cirrhotic population could aid earlier detection of the disease and decrease the cancer related mortality rate, our present success is limited by lack of sensitive biomarker (*Bruix & Llovet, 2002*).

Currently standard surveillance includes a combination of 6 monthly abdominal ultrasound scan and serum alpha-fetoprotein measurement, but this strategy does not reliably detect early disease. The diagnostic performance of alpha-

fetoprotein is inadequate (**Sherman. 2001**) as it is only elevated in 40-60% of cases, while abdominal ultrasonography is difficult in cirrhotic nodular livers and notoriously user dependant (**Bruix et al., 2001**).

The oncofetal antigen glypican-3(GPC-3) is a heparan sulfate proteoglycans that is expressed more than 70% of Hepatocellular carcinoma (**Capuro et al 2005**).

When combined with AFP it has sensitivity of up to 82% for HCC detection on a background of viral hepatitis (**Capurro et al., 2005**). Measurement of (GPC3) may be of help in the early detection of Hepatocellular carcinoma (**Beale et al,2008**).

Glypican-3 is a member of the glypican family of heparin sulfate proteoglycans, which are linked to the cell surface through a glycosylphosphatidylinositol anchor (**Filmus,2001**). GPC3 has been reported to be expressed in the majority (more than 70%) of Hepatocellular carcinoma as a diagnostic marker (**Jia et al., 2007**).

Aim of the Work

The aim of the present study is:

To evaluate the diagnostic value of glypican-3 (GPC3) in serum for primary hepatocellularcarcinoma (HCC).